Treatment of UTIs Due to Carbapenemase-Producers: How to Use New Antibiotic Drugs? A Narrative Review

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2021 Nov 27

PMID 34827272

Citations 8

Authors

Caroline Chapelle

Benjamin Gaborit

Raphaelle Dumont

Aurelien Dinh

Maxime Vallee

Affiliations

Soon will be listed here.

Abstract

Background: is one of the bacteria most frequently causing health care-associated urinary tract infections, and increasingly incriminating carbapenemase producers (KPCp). Most infections caused by KPCp are nosocomial and might cause serious issues, even leading to death in half of the reported cases. Our aim was to identify the best strategy, based on available scientific data, for the use of new antibiotic treatments to manage KPCp UTIs.

Methods: this narrative review of the literature was performed according to the criteria of preferred reporting items for systematic review and meta-analyses statement (PRISMA) (2020).

Results And Conclusions: KPCp-UTIs are a real challenge for physicians. While cefiderocol, meropenem-vaborbactam, ceftazidim-avibactam, and imipenem-relebactam represent a major step forward in the treatment of these UTIs, no guidelines are currently available, in view of choosing the most appropriate treatment, in each specific case.

Citing Articles

Prediction of higher ceftazidime-avibactam concentrations in the human renal interstitium compared with unbound plasma using a minimal physiologically based pharmacokinetic model developed in rats and pigs through microdialysis.

Vallee M, Aranzana-Climent V, Moreau J, Lamarche I, Fontanier T, Barc C Antimicrob Agents Chemother. 2025; 69(3):e0151824.

PMID: 39912660 PMC: 11881572. DOI: 10.1128/aac.01518-24.

A Possible Tool for Guiding Therapeutic Approaches to Urinary Infections with : Analyzing a Dataset from a Romanian Tertiary Hospital.

Lazar D, Nica M, Codreanu D, Kosa A, Visinescu L, Popescu C Antibiotics (Basel). 2025; 13(12.

PMID: 39766560 PMC: 11672808. DOI: 10.3390/antibiotics13121170.

Influence of preoperative urine culture and bacterial species on urogenital sepsis after ureteral flexible lithotripsy in patients with upper urinary tract stones.

Wang L, Yu X, Qiu Z, Liu P, Tian W, He W Front Med (Lausanne). 2024; 11:1393734.

PMID: 38765255 PMC: 11099900. DOI: 10.3389/fmed.2024.1393734.

Hybrid Sequencing-Based Genomic Analysis of from Urinary Tract Infections Among Inpatients at a Tertiary Hospital in Beijing.

Zhang W, Wang Y, Wang K, Li J, Liu J, Li S Infect Drug Resist. 2024; 17:1447-1457.

PMID: 38628244 PMC: 11020236. DOI: 10.2147/IDR.S448253.

"One Health" perspective on prevalence of co-existing extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae: a comprehensive systematic review and meta-analysis.

Ramatla T, Mafokwane T, Lekota K, Monyama M, Khasapane G, Serage N Ann Clin Microbiol Antimicrob. 2023; 22(1):88.

PMID: 37740207 PMC: 10517531. DOI: 10.1186/s12941-023-00638-3.

References

Pang F, Jia X, Zhao Q, Zhang Y . Factors associated to prevalence and treatment of carbapenem-resistant Enterobacteriaceae infections: a seven years retrospective study in three tertiary care hospitals. Ann Clin Microbiol Antimicrob. 2018; 17(1):13. PMC: 5865290. DOI: 10.1186/s12941-018-0267-8. View

Rhee E, Rizk M, Calder N, Nefliu M, Warrington S, Schwartz M . Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants. Antimicrob Agents Chemother. 2018; 62(9). PMC: 6125551. DOI: 10.1128/AAC.00280-18. View

King M, Heil E, Kuriakose S, Bias T, Huang V, El-Beyrouty C . Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections. Antimicrob Agents Chemother. 2017; 61(7). PMC: 5487633. DOI: 10.1128/AAC.00449-17. View

Sims M, Mariyanovski V, McLeroth P, Akers W, Lee Y, Brown M . Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother. 2017; 72(9):2616-2626. DOI: 10.1093/jac/dkx139. View

Bush K, Bradford P . Epidemiology of β-Lactamase-Producing Pathogens. Clin Microbiol Rev. 2020; 33(2). PMC: 7048014. DOI: 10.1128/CMR.00047-19. View

Zhanel G, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F . Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. Drugs. 2016; 76(5):567-88. DOI: 10.1007/s40265-016-0545-8. View

Neuner E, Yeh J, Hall G, Sekeres J, Endimiani A, Bonomo R . Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis. 2011; 69(4):357-62. PMC: 3058153. DOI: 10.1016/j.diagmicrobio.2010.10.013. View

Papadimitriou-Olivgeris M, Bartzavali C, Lambropoulou A, Solomou A, Tsiata E, Anastassiou E . Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam. J Antimicrob Chemother. 2019; 74(7):2051-2054. DOI: 10.1093/jac/dkz125. View

Logan L, Weinstein R . The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace. J Infect Dis. 2017; 215(suppl_1):S28-S36. PMC: 5853342. DOI: 10.1093/infdis/jiw282. View

10.

Rodriguez-Gomez J, Perez-Nadales E, Gutierrez-Gutierrez B, Machuca I, Martinez-Martinez L, Rivera F . Prognosis of urinary tract infection caused by KPC-producing Klebsiella pneumoniae: The impact of inappropriate empirical treatment. J Infect. 2019; 79(3):245-252. DOI: 10.1016/j.jinf.2019.06.014. View

11.

Bilinskaya A, Linder K, Kuti J . Plazomicin: an intravenous aminoglycoside antibacterial for the treatment of complicated urinary tract infections. Expert Rev Anti Infect Ther. 2020; 18(8):705-720. DOI: 10.1080/14787210.2020.1759419. View

12.

Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira J, Ariyasu M . Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018; 18(12):1319-1328. DOI: 10.1016/S1473-3099(18)30554-1. View

13.

Wagenlehner F, Sobel J, Newell P, Armstrong J, Huang X, Stone G . Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. Clin Infect Dis. 2016; 63(6):754-762. PMC: 4996135. DOI: 10.1093/cid/ciw378. View

14.

Patel G, Bonomo R . "Stormy waters ahead": global emergence of carbapenemases. Front Microbiol. 2013; 4:48. PMC: 3596785. DOI: 10.3389/fmicb.2013.00048. View

15.

Wu G, Cheon E . Meropenem-vaborbactam for the treatment of complicated urinary tract infections including acute pyelonephritis. Expert Opin Pharmacother. 2018; 19(13):1495-1502. DOI: 10.1080/14656566.2018.1512586. View

16.

Leone S, Cascella M, Pezone I, Fiore M . New antibiotics for the treatment of serious infections in intensive care unit patients. Curr Med Res Opin. 2019; 35(8):1331-1334. DOI: 10.1080/03007995.2019.1583025. View

17.

Ito-Horiyama T, Ishii Y, Ito A, Sato T, Nakamura R, Fukuhara N . Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases. Antimicrob Agents Chemother. 2016; 60(7):4384-6. PMC: 4914688. DOI: 10.1128/AAC.03098-15. View

18.

Lob S, Hackel M, Kazmierczak K, Young K, Motyl M, Karlowsky J . Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program). Antimicrob Agents Chemother. 2017; 61(6). PMC: 5444184. DOI: 10.1128/AAC.02209-16. View

19.

Nordmann P, Poirel L . Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria. Clin Infect Dis. 2019; 69(Suppl 7):S521-S528. PMC: 6853758. DOI: 10.1093/cid/ciz824. View

20.

Nordmann P, Naas T, Poirel L . Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011; 17(10):1791-8. PMC: 3310682. DOI: 10.3201/eid1710.110655. View